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Abstract
Sphingosine kinase 1 (SphK1) upregulation is associated with pathologic pulmonary vascular remodeling
in pulmonary arterial hypertension (PAH), but the mechanisms controlling its expression are undefined. In
this study, we sought to characterize the regulation of SphK1 expression by micro-RNAs (miRs). In silico
analysis of the SphK1 3′-untranslated region identified several putative miR binding sites, with miR-1-3p
(miR-1) being the most highly predicted target. Therefore we further investigated the role of miR-1 in
modulating SphK1 expression and characterized its effects on the phenotype of pulmonary artery smooth
muscle cells (PASMCs) and the development of experimental pulmonary hypertension in vivo. Our results
demonstrate that miR-1 is downregulated by hypoxia in PASMCs and can directly inhibit SphK1
expression. Overexpression of miR-1 in human PASMCs inhibits basal and hypoxia-induced proliferation
and migration. Human PASMCs isolated from PAH patients exhibit reduced miR-1 expression. We also
demonstrate that miR-1 is downregulated in mouse lung tissues during experimental hypoxia-mediated
pulmonary hypertension (HPH), consistent with upregulation of SphK1. Furthermore, administration of
miR-1 mimics in vivo prevented the development of HPH in mice and attenuated induction of SphK1 in
PASMCs. These data reveal the importance of miR-1 in regulating SphK1 expression during hypoxia in
PASMCs. A pivotal role is played by miR-1 in pulmonary vascular remodeling, including PASMC
proliferation and migration, and its overexpression protects from the development of HPH in vivo. These
studies improve our understanding of the molecular mechanisms underlying the pathogenesis of pulmonary
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hypertension.
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INTRODUCTION
Pulmonary arterial hypertension (PAH) is a progressive and fatal disease for which the pathogenic
mechanisms are poorly understood and no curative treatments are available (40). PAH is characterized by
increases in pulmonary vascular resistance primarily due to uncontrolled pulmonary vascular remodeling,
sustained vasoconstriction, or thrombosis in situ (15, 27). Rampant pulmonary artery smooth muscle cell
(PASMC) proliferation and apoptosis resistance contribute to increases in pulmonary vascular resistance
and pulmonary artery pressure (58), resulting in eventual right ventricular hypertrophy and heart failure, the
major cause of death in PAH. Most current PAH therapies are limited to targeting pulmonary
vasoconstriction, and patients continue to have a poor long-term prognosis (26). Thus there is an imperative
need to understand the mechanisms contributing to pulmonary vascular remodeling to develop new
therapies.
The significance of sphingolipid signaling in pulmonary disease has recently emerged. Our group and
others have demonstrated that the bioactive lipid sphingosine-1-phosphate (S1P) is involved in the
pathogenesis of pulmonary fibrosis and bronchopulmonary dysplasia and in regulation of the vascular
endothelial barrier during acute lung injury (14, 18, 22, 41, 43, 48, 50). S1P mediates many important
biological functions including cell proliferation, differentiation, motility, and resistance to apoptosis (12),
and its synthesis in the lungs and blood is predominantly regulated by sphingosine kinase 1 (SphK1; 17).
SphK1, a highly conserved, oncogenic enzyme, has itself been implicated in the promotion of cell
proliferation, apoptosis resistance, and angiogenesis (36, 51), and preclinical studies have shown the
efficacy of SphK1 inhibition in decreasing tumor size (16, 31). We have recently demonstrated that SphK1
and S1P are elevated in PAH and promote human PASMC (hPASMC) proliferation (7, 52). Additionally,
we found that genetic deficiency or pharmacologic inhibition of SphK1 in vivo protects against the
development of hypoxia-induced experimental pulmonary hypertension in mice (7). However, the
mechanisms involved in the hypoxia-mediated upregulation of SPHK1 expression in PAH and its
contribution to hPASMC proliferation are presently not well understood. In this study, we aimed to identify
novel molecular mechanisms of hypoxia-induced hPASMC proliferation, focusing on the role of SphK1
expression and its regulation by micro-RNAs (miRs).
As small, noncoding RNAs, miRs play important regulatory roles in animals and plants by base pairing
with complementary sequences within mRNA molecules, resulting in cleavage, translational repression, or
destabilization (1, 3, 42). The importance of miRs in modulating complex gene expression networks (32)
and their contributions to human disease pathogenesis have emerged, including in the field of
cardiovascular biology (49). Recent studies have identified several miRs associated with cell-specific
phenotypes in PAH and experimental models of pulmonary hypertension (4, 63). A systems-level
regulation of micro-RNA networks by miR-130/301 and their targeting of peroxisome proliferator-
activated receptor-γ (PPARγ) has been shown to promote pulmonary hypertension by distinct modulation
of both PASMCs and pulmonary artery endothelial cells (PAECs; 4). Another recent study demonstrated
that both miR-138 and miR-25 downregulate the mitochondrial calcium uniporter complex (MCUC),
causing a cancerlike proliferative phenotype in PASMCs in PAH (25). In addition, the bone morphogenetic
protein (BMP) signaling pathway, which has been widely shown to modulate vascular remodeling in PAH,
was recently found to be controlled by miR-140-5p (46). The regulation of miR expression by hypoxia and
their involvement in modulating the phenotype of smooth muscle cells (SMCs) have also been described
(6, 8).
Arterial SMCs, unlike cardiac and skeletal myocytes, can switch to a highly proliferative and migratory
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state under various stimuli, including hypoxia and vascular injury (21). We hypothesized that hypoxia
induces downregulation of micro-RNAs targeting SphK1, contributing to enhanced hPASMC proliferation
and migration. In this study, we demonstrate that miR-1 is decreased in PASMCs of PAH patients and is
downregulated by hypoxia, a major contributor to PAH development, in both cultured PASMCs and in lung
tissues from experimental models of PH. In addition, overexpression of miR-1 protected mice from
hypoxia-induced pulmonary hypertension (PH) and suppressed the expression of SphK1, a conserved lipid
kinase that catalyzes formation of the proproliferative and promigratory lipid S1P.
MATERIALS AND METHODS
Human pulmonary artery smooth muscle cells
(hPASMCs) were isolated from six donors not suitable for lung transplantation and four patients with
idiopathic PAH as previously described (2). The smooth muscle phenotype of cultured cells has been
authenticated by immunohistochemistry and flow cytometric analysis with antibodies against smooth
muscle α-actin and calponin (2). In addition to these cell lines, a male primary hPASMC cell line from
Lonza (CC-2581) was used for cell transfection, migration, and proliferation assays at passages 4–8. The
miR-1 mimics, inhibitors (antagomirs), or controls (50–100 nmol/l; Qiagen) were transfected using
Lipofectamine (Thermo Fisher Scientific) per the manufacturer’s instructions.
Cell proliferation was determined using a 5-bromo-2′-deoxyuridine (BrdU)
incorporation assay (QIA58; Calbiochem) per the manufacturer’s instructions in a 96-well format. Starting
cell densities of 4,000 cells per well were used.
Cell migration was determined using a quantitative Transwell assay as previously
described (35). In brief, cell migration across a Transwell membrane with 8-μm pores was assessed
following incubation in normoxic or hypoxic (3% O ) conditions. Cells were fixed and stained using Diff-
Quik, and the ratio of migrated to total cells was assessed via five random fields per sample. For miR
transfection studies, cells were transfected 24 h before transferring to the Transwell insert.
In silico analysis for miR target prediction was
completed using the microRNA.org target prediction resource (http://34.236.212.39/microrna/home.do),
utilizing miRanda sites and miR support vector regression (mirSVR) scoring (5). The target sites predicted
using miRanda are scored for likelihood of mRNA downregulation using a regression model trained on
sequence and contextual features of the predicted miRNA:mRNA duplex. Using these tools, hsa-miR-1-3p
was selected as a miR candidate targeting SPHK1.
For all miR transfection studies, miScript miRNA-1
mimics or antagomirs were used (Qiagen) per the manufacturer’s guidelines, with AllStars negative control
small interfering RNA (siRNA) used to account for nonsequence effects. The reporter construct containing
the firefly luciferase gene fused to the the full-length human SPHK1 3′-untranslated region (UTR) within
the pMirTarget vector was ordered from OriGene Technologies. This vector was cotransfected with a
control vector expressing a hRluc Renilla luciferase reporter gene and a herpes simplex virus thymidine
kinase (HSV-TK) promoter for normalization of transfection efficiency (pGL4.74[hRluc/TK]; Promega).
All transfections were performed in triplicate. At passages 4–8, hPASMCs were grown to 75% confluence
before transfection with miR mimics (50–100 nmol/l) or antagomirs (100 nmol/l) with controls of the same
concentrations using Lipofectamine (Thermo Fisher Scientific) per the manufacturer’s instructions. Cells
were harvested for downstream analysis 24–72 h posttransfection. For luciferase reporter assays, cells were
transfected concurrently with reporter vectors or controls. Cells were harvested at 24 h, and luciferase
activity was measured with the Dual Luciferase Reporter Assay System (Promega) per the manufacturer’s
protocol, using a GloMax luminometer (Promega). Transfection efficiency was determined by normalizing
firefly luciferase light units to Renilla luciferase light units. Results are representative of at least three
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independent experiments.
Lung tissues were perfused with PBS to remove blood and homogenized using
radioimmunoprecipitation assay buffer (Sigma) supplemented with protease and phosphatase inhibitor
cocktails (Calbiochem). Cells were washed with PBS, and protein was extracted using the same modified
radioimmunoprecipitation assay buffer solution. Proteins (10–25 μg) were separated on Mini-Protean TGX
precast gels (Bio-Rad), transferred to nitrocellulose membranes, and blocked in 5% nonfat dry milk.
Membranes were then probed with primary and secondary antibodies, and bands were visualized by
enhanced chemiluminescence (Pierce) per the manufacturer’s instructions. Densitometry was used to
quantify protein levels using ImageJ software, and expression levels were normalized to GAPDH or
β-actin. The primary antibodies used were SphK1, GAPDH, and horseradish peroxidase-conjugated β-actin
(Cell Signaling Technology) with specificity previously determined (7, 59). An anti-rabbit IgG, horseradish
peroxidase-linked secondary antibody was used (Cell Signaling Technology).
Paraffin-embedded mouse lung tissue sections were used
for immunostaining following antigen retrieval, using rabbit SphK1 (cat. no. ab71700; Abcam) and cyanine
3 (Cy3)-labeled mouse smooth muscle actin antibodies as previously described (30). The secondary
antibody used for SphK1 was Alexa Fluor 488 donkey anti-rabbit IgG (Thermo Fisher Scientific).
Mounting media with 4′,6-diamidino-2-phenylindole (DAPI; Life Science) were used to fix the coverslip to
a slide. Slides were examined using a Nikon Eclipse E800 fluorescence microscope.
Total RNA containing miRNA was isolated
from hPASMC and lung tissue samples using a miRNeasy kit (Qiagen) and reverse transcribed with the
miScript II RT kit (Qiagen). For real-time PCR, miRNA-specific miScript primer assays (Qiagen) were
used with RNU6-2 as an internal control. Expression of mRNAs was determined using specific TaqMan
primer assays (Applied Biosystems) with GAPDH used as an internal control. Relative changes in mRNA
and miRNA expression were calculated using the comparative cycle threshold method.
S1P levels from hPASMCs were measured using an
established method previously described (60). Briefly, total lipid extracts were extracted from cell cultures
after exposure to experimental conditions and then subjected to thin-layer chromatography and
autoradiography. The areas corresponding to labeled [ P]S1P were excised, and radioactivity was
determined by scintillation counting. The data were normalized to total radioactivity in 10  cells.
Terminal deoxynucleotidyl
transferase dUTP nick-end labeling (TUNEL) assays were performed as previously described (28). In brief,
hPASMCs at passages 4–8 were grown to 75% confluence before transfection with miR mimics (50–100
nmol/l) with controls of the same concentrations using Lipofectamine (Thermo Fisher Scientific) per the
manufacturer’s instructions. TUNEL assays were then performed at 24 h with nuclear DAPI costaining. For
quantitative analysis, TUNEL-positive apoptotic cells in ≥5 high-power fields per condition were expressed
as percent apoptotic cells compared with controls.
All experimental protocols using
vertebrate animals were reviewed and approved by the University of Illinois at Chicago Animal Care and
Use Committee. All experiments were performed in accordance with the approved guidelines and
regulations for the use of laboratory animals. In the mouse model of hypoxia-mediated pulmonary
hypertension (HPH), 8-wk-old male C57BL/6 mice were exposed to normoxia or hypoxia (10% O  in a
ventilated chamber) for 1 day to 4 wk (n = 3–5 per group). HPH development was assessed by measuring
right ventricular systolic pressure via a pressure transducer catheter (Millar) and right ventricular
hypertrophy as a weight ratio of the right ventricle divided by the sum of left ventricle and septum [RV/(LV
+ S)]. Pulmonary artery vessel thickness was calculated as [(external vessel area − internal vessel
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area)/external vessel area], as previously described (7), using images of lung histological sections (Aperio
ImageScope). Lung and heart tissues were collected for further analysis.
For mouse HPH prevention studies, animal-grade mirVana miRNA mimics or negative miRNA control no.
1 (Thermo Fisher) were prepared with Invivofectamine 3.0 reagent (Thermo Fisher) per the manufacturer’s
instructions and injected retroorbitally (7.8 mg/kg body wt) weekly for 4 wk starting 1 day before exposure
to normoxia or hypoxia (10% O ). HPH development was assessed as described above.
Results are shown as means ± SE from at least three experiments, and statistical
significance was calculated with Student’s t-test (*P < 0.05, **P < 0.01, ***P < 0.001 vs. controls) using
GraphPad Prism software.
RESULTS
To investigate the potential
regulation of SphK1 by miRs, we performed in silico analysis of the human SphK1 3′-UTR to identify
predicted miR response elements. This approach identified several putative binding sites, including
miR-1-3p (miR-1) as the most highly predicted target of SphK1 with a high probability of downregulation
(7-mer-m8 canonical site type, mirSVR score = −0.6270; 5). Suggesting its importance in gene regulation,
miR-1 and its SphK1 3′-UTR binding site are highly evolutionarily conserved across species. As
bioinformatics analysis identified the putative binding site of miR-1 within the 3′-UTR of SPHK1, we
hypothesized that this miR-1 may be a negative regulator of SphK1 expression in hPASMCs. To test this
hypothesis, we utilized a luciferase reporter vector containing a sequence-verified clone of the SphK1
3′-UTR designed for micro-RNA target validation. To determine the interaction of miR-1 with the SphK1
3′-UTR, we overexpressed or inhibited miR-1 expression using human miR-1 mimics or antagomirs,
respectively, in hPASMCs cotransfected with the SphK1 3′-UTR reporter vector. Overexpression of miR-1
resulted in reduced luciferase activity due to SphK1 3′-UTR binding, while transfection of miR-1
antagomirs had no effect (Fig. 1, A and B). In addition, both protein and mRNA expression levels of SphK1
were significantly decreased in hPASMCs following transfection with the miR-1 mimics (Fig. 1, C and D,
respectively), while miR-1 antagomirs did not alter SphK1 expression (data not shown). Transfection of
hPASMCs with miR-1 mimics also prevented hypoxia-induced generation of intracellular S1P generation
at 48 h but did not alter basal levels of S1P under normoxic conditions (Fig. 1E), demonstrating a
mechanistic role of miR-1 in limiting S1P production in hypoxia.
Hypoxia is associated with the pathogenesis of PAH and contributes to pulmonary vascular remodeling. We
utilized a mouse model of experimental HPH to investigate the development of disease progression
following 1, 7, 14, and 28 days of 10% O  exposure, assessed by the measurement of right ventricular
systolic pressure (RVSP) and right ventricular hypertrophy (RVH). Mice developed significant elevations
in RVSP by day 14 and increased RVH and heart weight-to-body weight ratio by day 7, with increased
severity of these parameters by day 28 (Fig. 2, A–C). Interestingly, the expression of miR-1 in whole lung
was significantly reduced over time following hypoxia exposure (Fig. 2D), and this paralleled an increase
in lung SphK1 protein expression (Fig. 2E). Significant elevation in vessel wall thickness of small
pulmonary arteries, due to medial hypertrophy of PASMCs, was also observed by day 28 (data not shown),
consistent with prior reports (7). These results demonstrate the utility of the HPH mouse model in studying
the role of miR-1 expression.
Since miR-1 was reduced in lungs from HPH mice, we investigated whether PASMCs isolated from
2
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miR-1 regulates the proliferation of hPASMCs.
miR-1 regulates the migration of hPASMCs.
Systemic miR-1 delivery protects from the development of HPH.
patients with PAH had altered levels of miR-1. Expression of miR-1 was significantly reduced in PASMCs
from PAH patients vs. controls (Fig. 3A). We then tested whether hypoxia could alter miR-1 expression in
hPASMCs. Hypoxia exposure (3% O ) increased the proliferative phenotype of hPASMCs over time (
Fig. 3B) and significantly reduced the expression of miR-1 normalized to RNU6-2 expression (Fig. 3C).
These data are consistent with our hypothesis that hypoxia may downregulate miR-1, leading to increased
SphK1 expression and enhanced cell proliferation. Since overexpression of miR-1 mimics in hPASMCs
can reduce SphK1 protein expression under normoxic conditions (Fig. 1C), we tested whether it could also
prevent the induction of SphK1 expression by hypoxia. As shown in Fig. 3, D and E, miR-1 overexpression
attenuates SphK1 expression under hypoxic conditions in hPASMCs over time, suggesting a significant
role of miR-1 in directly targeting the 3′-UTR of SphK1. The transient transfection of miR-1 mimics
sustained expression at 72 h, with the most robust expression at 24 h (data not shown).
Because miR-1 is significantly decreased in the hypoxia-
induced proliferative state of hPASMCs, we investigated whether altering miR-1 levels with the
transfection of miR-1 mimics could alter the proliferative phenotype in these cells. Overexpression of
miR-1 mimics at increasing concentrations reduced the proliferative capacity of hPASMCs in both
normoxic and hypoxic conditions, respectively (Fig. 4, A and B). Differences in proliferation were also
observed by light microscopy, with a substantial reduction in the number of hPASMCs in both normoxia
and hypoxia following miR-1 overexpression (Fig. 4, C and D). The proliferative changes induced by
miR-1 were not caused by enhanced cytotoxicity, as measured via lactate dehydrogenase activity in cell
supernatants (data not shown). TUNEL assays demonstrated an ~11% induction of apoptosis in hPASMC
transfection with miR-1 mimics at the highest dose of 100 nmol/l (Fig. 4, E and F). Although this finding
may contribute to the antiproliferative effects of miR-1 in hPASMCs, the low level of apoptosis induced by
miR-1 mimics is unlikely to account for the significant impact on proliferation observed.
Both hPASMC proliferation and migration contribute to
pathogenic pulmonary vascular remodeling in PAH. On the basis of the findings that miR-1 overexpression
greatly reduced hPASMC proliferation in vitro, we tested whether miR-1 overexpression could also
attenuate normoxic or hypoxia-induced hPASMC migration. In a Transwell assay, hPASMCs migrated over
time under normoxic conditions, and as expected, migration increased when these cells were exposed to
hypoxia for 12–48 h (Fig. 5, A and B). Overexpression of miR-1 inhibited the migration of hPASMCs at
normoxia and further reduced the migration under hypoxic conditions (Fig. 5, C and D). This significant
reduction in migratory capacity under hypoxic conditions demonstrates the importance of diminished
miR-1 expression during this synthetic state of hPASMCs. Thus reduced miR-1 expression in hypoxia can
enhance both proliferation and migration in this cell type during in vitro conditions that contribute to
pulmonary vascular remodeling.
To test whether increasing expression
of miR-1 in vivo could prevent HPH development, we delivered either nontargeting or miR-1 mimics via
retroorbital injection to mice weekly throughout their 4-wk hypoxia course. Compared with controls, mice
receiving miR-1 mimics were protected against the development of HPH, with significant attenuation of
RVSP elevation and RVH (Fig. 6, A–C). Hypoxia-induced pulmonary vascular remodeling was also
reduced with miR-1 mimic treatment (Fig. 6, D–F). No changes were observed in any of these parameters
under normoxic conditions with miR-1 administration. Systemic administration of miR-1 mimics prevented
the reduction in miR-1 expression induced by hypoxia, which resulted in a fourfold to fivefold increase in
expression in the lung (Fig. 6G). To test whether increased miR-1 expression altered SphK1 expression in
this model, we measured SphK1 protein in lung tissues. Overexpression of miR-1 had no significant effect
on SphK1 under normoxic conditions but reduced SphK1 expression induction with hypoxia exposure (
Fig. 7, A and B). To test whether SphK1 expression was altered in mouse PASMCs receiving miR-1
mimics, we measured both SphK1 and α-smooth muscle actin (α-SMA), a marker for smooth muscle cells,
2
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by immunofluorescence imaging in histological lung sections. SphK1 expression colocalized with α-SMA
and was significantly reduced in mice receiving miR-1 mimics in both normoxic and hypoxic conditions (
Fig. 7C). These results indicate that overexpression of miR-1 mimics reduces the development of
experimental HPH and, together with the in vitro data presented in this study, suggest that altered
expression of SphK1 expression by miR-1 may contribute to disease pathogenesis.
DISCUSSION
PAH is a devastating lung disease for which curative treatments are unavailable and patient morbidity and
mortality remain high (26, 40). Despite active research in uncovering the pathogenic mechanisms resulting
in this disease, therapies targeting the prevention or reversal of pulmonary vascular remodeling and
subsequent elevations in pulmonary arterial pressure have not been successful. The present study provides
evidence of the role of miR-1, a muscle-specific micro-RNA, and its posttranscriptional regulation of
SphK1 in the pathogenesis of PAH and highlights its potential as a novel therapeutic target.
In the present study, using an in silico approach, we identify miR-1 as a potential regulator of SphK1
expression. We found that miR-1 is highly downregulated by hypoxia in hPASMCs, as well as in the lungs
of mice throughout the progression of experimental HPH, coincident with increased SphK1 expression.
Expression of miR-1 was also significantly reduced in PASMCs isolated from patients with PAH. Hypoxia-
mediated decreases in miR-1 expression were associated with enhanced hPASMC proliferation and
migration in vitro, and overexpression of miR-1 inhibited these effects. Additionally, we provide in vivo
evidence that miR-1 overexpression prevents the development of experimental HPH and reduces the
overexpression of SphK1 in PASMCs in this model. Although there are likely multiple mRNA targets of
miR-1, the regulation of SphK1 expression is consistent with our findings that this kinase is highly
influential in promoting PASMC proliferation and the development of experimental pulmonary
hypertension (7). These experiments describe a novel role of miR-1 in regulating the intricate molecular
mechanisms underlying pathogenic pulmonary vascular remodeling in PAH.
Our previous work has demonstrated that elevated levels of both S1P and SphK1 in the lung are associated
with PAH (7). These studies showed that both genetic knockout of SphK1 in mice and pharmacologic
SphK1 inhibition in rats could prevent the development of hypoxia-mediated PH. Inhibiting the S1P
receptor 2 (S1PR2) in mice also prevented PH development, and mice heterozygous for S1P lyase, which
catabolizes S1P, were more susceptible to PH (7). Together, these studies define the role of SphK1-S1P
signaling in PAH. Here we identified miR-1 as a negative regulator of SphK1 expression. Under basal
conditions, normal miR-1 expression limits SphK1 expression, whereas in hypoxia the reduction in miR-1
allows for SphK1 upregulation at both mRNA and protein levels.
Unrestrained PASMC proliferation and migration, as well are hypoxic vasoconstriction, are major
contributors to pulmonary vascular remodeling in PAH, and upregulation of the SphK1-S1P signaling axis
has been implicated in these pathogenic processes (7, 11, 53). We have previously demonstrated that both
overexpression of SphK1 and stimulation with S1P promote the proliferative phenotype of hPASMCs.
Several studies have also reported that miRNAs can regulate cell proliferation and migration associated
with vascular remodeling by several mechanisms, including targeting of ion channels, mitochondrial
function, and BMP receptor 2 (BMPR2) signaling pathways (19). Here, we report that miR-1 is
downregulated in PASMCs isolated from PAH patients and overexpression of miR-1 can reduce hypoxia-
induced SphK1 expression and attenuate PASMC proliferation and migration. These studies indicate the
critical role of miR-1 in regulating pulmonary vascular remodeling in PAH. The relevance of these findings
also extends beyond PAH, as SphK1 and S1P are well-known mediators of cell proliferation, apoptosis
resistance, and angiogenesis in myriad cell types, including cancer cells (36, 51).
Shared features of cancer development with the unrestricted vascular cell proliferation, apoptosis
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resistance, and glycolytic shifts of PAH have recently been appreciated (20, 44). In these studies, a
“pseudohypoxic environment” is proposed where glycolysis is predominant and hypoxia-inducible factor
1α is activated under normoxia (13, 47). These observations are consistent with our findings of reduced
miR-1 expression in PASMCs isolated from PAH patients in normoxic conditions. Importantly, inhibiting
the oncogenic properties of SphK1 has shown efficacy in preclinical studies to decrease tumor growth (16,
31), and therefore induction of miR-1 to limit SphK1 expression may be beneficial. Recent reports have
also associated downregulation of miR-1 with cancer development in various cell types (38, 39, 55, 56) via
its modulation of cell proliferation, migration, and invasion. These studies suggest the ubiquitous role of
miR-1 in the regulation of cell proliferation and are consistent with our findings that miR-1 is
antiproliferative in PASMCs.
In SMCs, miR-1 has also been reported to regulate gene expression. It is an important modulator of cardiac
and skeletal muscle proliferation, with excess expression leading to a reduced pool of proliferating
ventricular cardiomyocytes in vivo (9, 61, 62). Expression of miR-1 can be induced by myocardin, a
transcriptional activator of serum response factor (SRF), to inhibit cell proliferation and contractility in
human vascular SMCs (8, 29), potentially through regulation of proviral integration site for Moloney
murine leukemia virus-1 (Pim-1), a recently identified biomarker in PAH (45). Downregulation of miR-1
has also been observed in vascular SMCs isolated from spontaneously hypertensive rats and may regulate
proliferation by targeting insulin-like growth factor I (IGF-I; 37), a growth factor involved in neonatal HPH
(57). In addition, genetic knockout of miR-1 in mice results in uniform lethality before weaning due to
cardiac dysfunction, and hearts from these mice exhibit gene expression characteristics more similar to
vascular smooth muscle (24). This suggests that the influence of miR-1 on the proliferation and migration
of PASMCs likely functions through multiple parallel mechanisms to achieve the resulting cellular
phenotype.
Micro-RNAs have shown promise as potential therapeutic targets and biomarkers for many diseases,
including PAH. Interestingly, a recent study exploring the role of circulating miRNAs in human PH
demonstrated reduced expression of miR-1 in the buffy coat of patients with both moderate and severe PH
(54). Here, we have demonstrated that miR-1 is strongly downregulated early in and throughout the course
of experimental hypoxia-induced PH in the lungs and that this downregulation is retained in PASMCs from
PAH patients. This suggests that miR-1 plays a role in early disease pathogenesis rather than having an
end-stage disease effect. Overexpression of miR-1 can reduce the pulmonary vascular remodeling
phenotype both in vitro and in vivo; therefore identifying mechanisms to elevate or sustain miR-1
expression in PAH may be beneficial.
There are several limitations to the present study that warrant further investigation. The ability of miR-1 to
decrease SphK1 levels in PASMCs is one mechanism through which it regulates vascular remodeling, but
other direct targets of miR-1 involved in PAH development may contribute to our findings here and would
be important to identify in future studies. Table 1 provides a list of the most highly predicted mRNA targets
of miR-1. This list includes two genes, brain-derived neurotrophic factor (BDNF) and gap junction α-1
protein/connexin 43 (GJA1/Cx43), that have been previously associated with PASMC pathobiology (10, 23,
33). Another potential limitation is that miR-1 overexpression induces apoptosis in hPASMCs, though the
low level of induction even at high mimic concentrations is unlikely to account for the significant impact
on proliferation we observed. Furthermore, in addition to unrestrained PASMC proliferation and apoptosis
resistance, pulmonary vascular remodeling involves neointimal formation due to PAEC dysfunction and
proliferation (34, 58). The studies described here did not investigate the role of the SphK1-S1P axis on the
phenotype of PAECs; this would provide valuable insight into disease mechanisms and deserves
exploration in future studies. Finally, though we have used idiopathic PAH samples in this study and
demonstrated a role of miR-1 under normoxic conditions in PASMCs, several of our experiments utilize
hypoxia as a model of disease, which more classically parallels group 3 PH. As discussed above, we
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believe that hypoxia and normoxic activation of hypoxia-related signaling pathways are fundamental to the
development of PAH and that our studies therefore offer important insights into this group of PH as well.
Together, these novel data demonstrate that miR-1 can target SphK1 to regulate molecular mechanisms in
PH with effects on PASMCs and pulmonary arterial remodeling. The activation of miR-1 in the pulmonary
vasculature may therefore provide therapeutic benefit in PH, a group of diseases in significant need of new
treatments.
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Fig. 1.
Open in a separate window
Micro-RNA-1 (miR-1) binds to the sphingosine kinase 1 (SphK1) 3′-untranslated region (SK1 3′UTR) and inhibits SphK1
expression. A and B: transfection of human pulmonary artery smooth muscle cells (hPASMCs) with miR-1 mimics (50
nmol/l), but not antagomirs (100 nmol/l), significantly reduces luciferase activity of a SphK1 3′-UTR reporter construct
relative to control (Ctrl). Overexpression of miR-1 mimic (50 nmol/l) in hPASMCs significantly decreases SphK1 protein
expression (C) and mRNA expression (D) at 48 h. E: transfection of hPASMCs with miR-1 mimics (50 nmol) prevents
hypoxia-induced generation of intracellular [ P]sphingosine-1-phosphate ([ P]S1P) generation at 48 h. Here, n ≥ 5 per
condition. *P < 0.05, ***P < 0.001 relative to control. NTC, nontargeting control; RLU, relative light units; N, normoxia;
H, hypoxia (3% O ); dpm, disintegrations per minute.
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Fig. 2.
Micro-RNA-1 (miR-1) is downregulated in mouse lungs during the progression of experimental hypoxia-mediated
pulmonary hypertension (HPH). A and B: HPH development in mice is demonstrated by elevations in right ventricular
systolic pressure (RVSP) and right ventricular hypertrophy [measured as a weight ratio of the right ventricle divided by the
sum of the left ventricle and septum, RV/(LV + S)] over time [day (D) 1–28 of hypoxia]. C: change in mouse heart weight-
to-body weight ratio over the course of HPH development. Expression of miR-1 normalized to RNU6-2 expression is
reduced (D) and sphingosine kinase 1 (SphK1) protein expression is increased (E) in mouse lungs during HPH
development. Here, n ≥ 5 per condition. *P < 0.05, **P < 0.01, ***P < 0.001 relative to control (Ctrl). N, normoxia; H,
hypoxia (3% O ).2
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Fig. 3.
Micro-RNA-1 (miR-1) is decreased in human pulmonary artery smooth muscle cells (hPASMCs) from pulmonary arterial
hypertension (PAH) patients, is downregulated by hypoxia, and prevents hypoxia-induced sphingosine kinase 1 (SphK1)
expression. A: miR-1 expression normalized to RNU6-2 expression is reduced in hPASMCs isolated from PAH patients (n
= 4) vs. controls (Ctrl; n = 6). B: stimulation of hPASMCs with hypoxia induces proliferation (24–48 h, 3% O ). C:
hypoxia (3% O ) induces downregulation of miR-1 expression over time in hPASMCs. D and E: miR-1 overexpression in
hPASMCs attenuates hypoxia-induced SphK1 protein expression (24–72 h, 50 nmol/l mimics). Here, n ≥ 5 per condition,
unless otherwise indicated. *P < 0.05, **P < 0.01, ***P < 0.001 relative to control. BrdU, 5-bromo-2′-deoxyuridine.
2
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Fig. 4.
Open in a separate window
Micro-RNA-1 (miR-1) overexpression inhibits human pulmonary artery smooth muscle cell (hPASMC) proliferation in
normoxia and hypoxia. Overexpression of miR-1 mimics in hPASMCs (50–100 nmol/l) significantly reduces proliferation
in normoxia (A) and hypoxia (3% O , 24–48 h; B). C and D: representative images of hPASMCs demonstrating miR-1
mimic overexpression in normoxia and hypoxia reduces the rate of proliferation (24 h, ×10 magnification). Representative
staining images (E) and quantification of terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) assay
(F) demonstrating induction of apoptosis at low levels by overexpression of miR-1 mimics (100 nmol/l) in hPASMCs (24
h, ×10 magnification). Data are represented as percentage of TUNEL-positive cells of total 4′,6-diamidino-2-phenylindole
(DAPI)-positive cells per high-power field per condition (≥5 fields counted). Here, n ≥ 5 per condition. **P < 0.01, ***P
< 0.001 relative to control (Ctrl). BrdU, 5-bromo-2′-deoxyuridine.
2
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Fig. 5.
Micro-RNA-1 (miR-1) overexpression inhibits human pulmonary artery smooth muscle cell (hPASMC) migration in
hypoxia. Stimulation of hPASMCs with hypoxia induces cell migration in a Transwell assay (12–48 h, 3% O ; A), with
representative images (×10 magnification; B). Overexpression of miR-1 mimics in hPASMCs (50 nmol/l) significantly
reduces hypoxia-induced cell migration in a Transwell assay (3% O , 24 h; C), with representative images (×10
magnification; D). Here, n ≥ 5 per condition. *P < 0.05, **P < 0.01, ***P < 0.001 relative to control (Ctrl), unless
otherwise indicated. #P < 0.05, ##P < 0.01, ###P < 0.001.
2
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Fig. 6.
Micro-RNA-1 (miR-1) overexpression in vivo prevents the development of hypoxia-mediated pulmonary hypertension
(HPH) in mice. Compared with controls (Ctrl), mice in the HPH model receiving systemic miR-1 mimics (7.8 mg/kg)
develop less severe right ventricular systolic pressure (RVSP) elevation (A and B), right ventricular hypertrophy
[calculated as a weight ratio of the right ventricle divided by the sum of left ventricle and septum, RV/(LV + S); C], and
pulmonary vascular remodeling in arteries with diameters D < 50 µM and 50–100 µM, respectively (D and E). F:
representative histological images of small pulmonary arteries in normoxia and hypoxia, with and without treatment of
systemic miR-1 mimics. Scale bar = 20 µm. G: systemic administration of miR-1 mimics (7.8 mg/kg) in mice resulted in a
fourfold to fivefold increase in lung expression in both normoxic (Nor) and hypoxic (Hyp) conditions, normalized to
RNU6-2 expression (24 h following final injection). Here, n ≥ 5 per condition. *P < 0.05, **P < 0.01 relative to control.
RVP, right ventricular pressure.
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Fig. 7.
Open in a separate window
Micro-RNA-1 (miR-1) overexpression in vivo reduces induction of sphingosine kinase 1 (SphK1) in the lungs and
pulmonary arteries. Representative Western blotting in whole lung tissues from mice with hypoxia-mediated pulmonary
hypertension (HPH) demonstrates attenuation of SphK1 expression following systemic miR-1 mimic administration (7.8
mg/kg; A), with data quantification relative to actin expression (B). C: immunofluorescence staining demonstrates that
hypoxia-induced SphK1 protein expression in small pulmonary arteries is reduced in miR-1 mimic-treated mice compared
with controls (Ctrl). Scale bars = 20 µm. *P < 0.05 relative to control. NS, not significant; SMC, smooth muscle cell.
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Table 1.
Predicted mRNA targets of miR-1 in human cells
Gene Symbol Gene Description mirSVR Score
ZNF280C Zinc finger protein 280C −3.21
BDNF Brain-derived neurotrophic factor −3.19
GJA1 Gap junction α-1 protein [connexin 43 (Cx43)] −3.03
KIF2A Kinesin family member 2A −2.42
SLC44A1 Solute carrier family 44 member 1 −2.29
FAM104B Family with sequence similarity 104 member B −2.19
YWHAQ Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein-θ −2.19
HACD3 3-Hydroxyacyl-CoA dehydratase 3 −2.11
MEX3C Mex-3 RNA-binding family member C −2.07
GLCCI1 Glucocorticoid-induced 1 −2.07
MGC70870 COOH-terminal binding protein-2 pseudogene −1.93
RP2 RP2, ARL3 GTPase-activating protein −1.92
UST Uronyl 2-sulfotransferase −1.89
CDK14 Cyclin-dependent kinase 14 −1.85
CHSY1 Chondroitin sulfate synthase 1 −1.85
Data were collected from microRNA.org (http://34.236.212.39/microrna/home.do); miR-1, micro-RNA-1; mirSVR,
miR support vector regression; ARL3, ADP-ribosylation factor-like protein-3; RP2, retinitis pigmentosa protein-2.
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